Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic Saline in Cystic Fibrosis
NCT00271310Phase 3Completed
- Sponsor
- Royal Prince Alfred Hospital
- Start
- Sep 2000
- Modality
- Small Molecules, Device-based Delivery
01
Overview
Phase 3, randomised trial of hypertonic saline in cystic fibrosis (CF) (2 arms), sponsored by Royal Prince Alfred Hospital. Primary endpoint: Lung function (FEV1, FVC, FEF25-75) at 336 days. Started Sep 2000; status: completed.
02
Drugs
hypertonic saline
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00271310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271310.